Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of tovorafenib in pediatric RAF-altered low-grade glioma and advanced solid tumors
NL-OMON59260Phase 2Recruiting
- Sponsor
- Day One Biopharmaceuticals
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tovorafenib in glioma and Nonhematologic neoplasms (3 arms), sponsored by Day One Biopharmaceuticals. Started Sep 2021; status: recruiting.
02
Drugs
tovorafenib
03
Conditions
gliomaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59260.